Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 (secukinumab) extension in RRMS
NCT01433250Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of secukinumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01433250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01433250.